Trials / NCT07862530
Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
Not yet recruiting Phase 2 Drug / neuroprotection
- Sponsor
- Yana Najjar
- Treatment
- RP2 (vusolimogene oderparepvec); Nivolumab; Definitive Surgical Resection
- Gene
- RP2
- Conditions
- MelanomaCutaneous Melanoma Resectable, Melanoma
- Ages
- 18 Years to no upper limit
- Enrollment
- 34 participants
- Started
- 2026-12-31
- Main results expected
- 2028-02-27
- Results posted
- Not yet
- Record last updated
- 2026-10-07
What the study is testing
This is a Phase II study is being done to determine whether a new combination of therapies is safe and effective for adults to treat Melanoma before surgery. The two therapies that will be combined in this study are nivolumab and RP2.
Nivolumab is a standard treatment for this type of cancer. Nivolumab targets and blocks a receptor called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 may activate T-cells to find and kill cancer cells.
RP2 is a new treatment that is not yet FDA approved to treat this cancer. RP2 is a herpes simplex virus (a microscopic life form commonly known as the "cold sore virus") that has been changed in the laboratory to grow in and destroy cancer cells and to activate (turn on) the immune system to attack the cancer cells.
Where it runs
United States (1)
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania